Combination therapy for EGFR-positive stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs—becotatugvedotin (which targets EGFR on cancer cells) and pucotenlimab (an immunotherapy that helps the immune system fight cancer)—for people with advanced stomach or GEJ cancer that is EGFR-positive and has progressed after one prior treatment. It aims to see if this combo can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You need a confirmed diagnosis of stomach or gastroesophageal junction (GEJ) cancer that is advanced, has returned, or cannot be removed with surgery.
- Your tumor must test positive for a protein called EGFR (done on a tissue sample).
- You must have already had one line of chemotherapy (with or without an immunotherapy like a PD-1 inhibitor), and your cancer has grown or you couldn't tolerate the treatment.
- You need to have at least one tumor that can be measured on scans.
- You should be in good general health (able to do light activities) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a combination of three drugs (adebrelimab, apatinib, and paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has progressed after immunotherapy. The goal is to see if this combination helps control the cancer longer.
This trial tests a combination of adebrelimab (an immunotherapy) with either two other experimental drugs (SHR-A1811 or SHR-A1904) plus chemotherapy, or another drug (SHR-8068), as a first treatment for gastric or gastroesophageal junction adenocarcinoma. It aims to find if these combos work better than standard care.
This trial tests whether adding two newer drugs (pucotenlimab and lenvatinib) to standard chemotherapy (SOX) works better than chemotherapy alone for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative. The goal is to see if the combination slows cancer growth.
This trial tests a new combination of two drugs—Becotatug Vedotin (a targeted therapy that delivers chemotherapy directly to EGFR-positive cancer cells) and Pucotenlimab (an immunotherapy that helps your immune system fight cancer). It is for people with advanced solid tumors that have not responded to standard treatments.
This trial is testing a combination of immunotherapy, anti-angiogenic (blood vessel blocker) therapy, and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that hasn't spread yet. It is for those whose tumors have a low PD-L1 score and who haven't had treatment for the advanced cancer before.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.